1. Market Research
  2. > A.P. Pharma, Inc. – Product Pipeline Review – 2013

A.P. Pharma, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

A.P. Pharma, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “A.P. Pharma, Inc. - Product Pipeline Review - 2013” provides data on the A.P. Pharma, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, A.P. Pharma, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from A.P. Pharma, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A.P. Pharma, Inc. - Brief A.P. Pharma, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of A.P. Pharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of A.P. Pharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the A.P. Pharma, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate A.P. Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of A.P. Pharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the A.P. Pharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with A.P. Pharma, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of A.P. Pharma, Inc. and identify potential opportunities in those areas.

Table Of Contents

A.P. Pharma, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
A.P. Pharma, Inc. Snapshot 5
A.P. Pharma, Inc. Overview 5
Key Information 5
Key Facts 5
A.P. Pharma, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
A.P. Pharma, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
A.P. Pharma, Inc. - Pipeline Products Glance 10
A.P. Pharma, Inc. - Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
A.P. Pharma, Inc. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
A.P. Pharma, Inc. - Drug Profiles 12
APF-505 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
granisetron 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
meloxicam 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
A.P. Pharma, Inc. - Pipeline Products by Route of Administration 16
A.P. Pharma, Inc. - Pipeline Products By Mechanism of Action 17
A.P. Pharma, Inc. - Recent Pipeline Updates 18
A.P. Pharma, Inc. - Dormant Projects 20
A.P. Pharma, Inc. - Company Statement 21
A.P. Pharma, Inc. - Locations And Subsidiaries 25
Head Office 25
A.P. Pharma, Inc., Recent Developments 26
A.P. Pharma, Inc.- Press Release 26
Mar 28, 2013: A.P. Pharma Receives FDA Complete Response Letter For APF530 For Prevention Of Chemotherapy-induced Nausea And Vomiting 26
Mar 22, 2010: A.P. Pharma Receives FDA Complete Response Letter For APF530 26
Financial Deals Landscape 28
A.P. Pharma, Inc., Deals Summary 28
A.P. Pharma, Inc., Pharmaceuticals and Healthcare, Deal Details 29
Equity Offering 29
A.P. Pharma Completes Private Placement Of Common Stock For $54 Million 29
A.P. Pharma Completes Private Placement Of Units For $24 Million 31
A.P. Pharma Completes First Tranche Private Placement Of $7.04 Million 33
A.P. Pharma Completes Public Offering Of $40 Million 35
Debt Offering 37
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For $1.5 Million 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

A.P. Pharma, Inc., Key Information 5
A.P. Pharma, Inc., Key Facts 5
A.P. Pharma, Inc. - Pipeline by Indication, 2013 7
A.P. Pharma, Inc. - Pipeline by Stage of Development, 2013 8
A.P. Pharma, Inc. - Monotherapy Products in Pipeline, 2013 9
A.P. Pharma, Inc. - Filed, 2013 10
A.P. Pharma, Inc. - Pre-Clinical, 2013 11
A.P. Pharma, Inc. - Pipeline By Route of Administration, 2013 16
A.P. Pharma, Inc. - Pipeline Products By Mechanism of Action, 2013 17
A.P. Pharma, Inc. - Recent Pipeline Updates, 2013 18
A.P. Pharma, Inc. - Dormant Developmental Projects,2013 20
A.P. Pharma, Inc., Deals Summary 28
A.P. Pharma Completes Private Placement Of Common Stock For $54 Million 29
A.P. Pharma Completes Private Placement Of Units For $24 Million 31
A.P. Pharma Completes First Tranche Private Placement Of $7.04 Million 33
A.P. Pharma Completes Public Offering Of $40 Million 35
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For $1.5 Million 37



List of Figures

A.P. Pharma, Inc. - Pipeline by Indication, 2013 7
A.P. Pharma, Inc. - Pipeline by Stage of Development, 2013 8
A.P. Pharma, Inc. - Monotherapy Products in Pipeline, 2013 9
A.P. Pharma, Inc. - Pipeline By Route of Administration, 2013 16
A.P. Pharma, Inc. - Pipeline Products By Mechanism of Action, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.